| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
|
N Engl J Med
|
2009
|
5.79
|
|
2
|
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.
|
Nature
|
2013
|
3.46
|
|
3
|
Identification and manipulation of tumor associated macrophages in human cancers.
|
J Transl Med
|
2011
|
2.39
|
|
4
|
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.
|
Nat Rev Cancer
|
2008
|
2.31
|
|
5
|
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
|
Clin Cancer Res
|
2008
|
2.06
|
|
6
|
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
|
Clin Cancer Res
|
2009
|
2.04
|
|
7
|
M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.
|
J Immunol
|
2011
|
2.02
|
|
8
|
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
|
Cancer Res
|
2007
|
1.96
|
|
9
|
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
|
J Immunol
|
2002
|
1.93
|
|
10
|
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
|
Cancer Res
|
2004
|
1.90
|
|
11
|
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
|
Proc Natl Acad Sci U S A
|
2010
|
1.67
|
|
12
|
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
|
Clin Cancer Res
|
2008
|
1.66
|
|
13
|
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.
|
Cancer Res
|
2010
|
1.59
|
|
14
|
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?
|
Clin Cancer Res
|
2008
|
1.54
|
|
15
|
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.
|
J Immunol
|
2007
|
1.54
|
|
16
|
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
|
Cancer Res
|
2003
|
1.40
|
|
17
|
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization.
|
Clin Cancer Res
|
2005
|
1.38
|
|
18
|
Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples.
|
PLoS Comput Biol
|
2013
|
1.35
|
|
19
|
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
|
Clin Cancer Res
|
2005
|
1.30
|
|
20
|
Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment.
|
Cancer Res
|
2013
|
1.28
|
|
21
|
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
|
J Exp Med
|
2007
|
1.28
|
|
22
|
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
|
Clin Cancer Res
|
2009
|
1.27
|
|
23
|
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
|
Int J Cancer
|
2009
|
1.26
|
|
24
|
Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes.
|
PLoS One
|
2011
|
1.26
|
|
25
|
A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses.
|
Int J Cancer
|
2010
|
1.25
|
|
26
|
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
|
Clin Cancer Res
|
2011
|
1.24
|
|
27
|
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.
|
J Biol Chem
|
2007
|
1.23
|
|
28
|
Therapeutic cancer vaccines.
|
J Clin Invest
|
2015
|
1.23
|
|
29
|
Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.
|
Cancer Res
|
2002
|
1.22
|
|
30
|
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.
|
Proc Natl Acad Sci U S A
|
2011
|
1.17
|
|
31
|
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
|
Eur J Immunol
|
2008
|
1.16
|
|
32
|
Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response.
|
PLoS Pathog
|
2013
|
1.15
|
|
33
|
Design and development of synthetic peptide vaccines: past, present and future.
|
Expert Rev Vaccines
|
2007
|
1.14
|
|
34
|
Neoantigen landscape dynamics during human melanoma-T cell interactions.
|
Nature
|
2016
|
1.12
|
|
35
|
Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
|
Clin Cancer Res
|
2003
|
1.12
|
|
36
|
Vaccination for treatment and prevention of cancer in animal models.
|
Adv Immunol
|
2006
|
1.11
|
|
37
|
Therapy of human papillomavirus-related disease.
|
Vaccine
|
2012
|
1.11
|
|
38
|
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen.
|
Cancer Res
|
2008
|
1.11
|
|
39
|
Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.
|
Int J Cancer
|
2008
|
1.11
|
|
40
|
Genetic variation of antigen processing machinery components and association with cervical carcinoma.
|
Genes Chromosomes Cancer
|
2007
|
1.11
|
|
41
|
Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides.
|
Hum Immunol
|
2003
|
1.07
|
|
42
|
Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
|
Clin Cancer Res
|
2006
|
1.06
|
|
43
|
Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding.
|
Expert Rev Vaccines
|
2008
|
1.06
|
|
44
|
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.
|
Int J Cancer
|
2010
|
1.06
|
|
45
|
The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects.
|
J Exp Med
|
2009
|
1.05
|
|
46
|
Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease.
|
Int J Cancer
|
2006
|
1.05
|
|
47
|
Harmonization of the intracellular cytokine staining assay.
|
Cancer Immunol Immunother
|
2012
|
1.05
|
|
48
|
Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
|
Pigment Cell Melanoma Res
|
2013
|
1.02
|
|
49
|
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
|
J Transl Med
|
2013
|
1.02
|
|
50
|
Tumor-specific regulatory T cells in cancer patients.
|
Hum Immunol
|
2008
|
1.01
|
|
51
|
An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
|
Cancer Res
|
2010
|
1.00
|
|
52
|
Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen.
|
Cancer Res
|
2008
|
0.99
|
|
53
|
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.
|
Cancer Immunol Immunother
|
2015
|
0.99
|
|
54
|
The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors.
|
Int J Cancer
|
2010
|
0.98
|
|
55
|
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.
|
Cancer Immunol Immunother
|
2012
|
0.98
|
|
56
|
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
|
Cancer Immunol Immunother
|
2012
|
0.97
|
|
57
|
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.
|
Semin Immunol
|
2013
|
0.96
|
|
58
|
Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC class I tetramers.
|
J Immunol
|
2003
|
0.95
|
|
59
|
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
|
Int J Cancer
|
2006
|
0.94
|
|
60
|
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
|
Int J Cancer
|
2012
|
0.94
|
|
61
|
Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2.
|
Mol Immunol
|
2012
|
0.94
|
|
62
|
Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer.
|
Curr Pharm Des
|
2012
|
0.94
|
|
63
|
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.
|
Eur J Immunol
|
2013
|
0.93
|
|
64
|
Intradermal delivery of TLR agonists in a human explant skin model: preferential activation of migratory dendritic cells by polyribosinic-polyribocytidylic acid and peptidoglycans.
|
J Immunol
|
2013
|
0.93
|
|
65
|
Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists.
|
Vaccine
|
2006
|
0.92
|
|
66
|
Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
|
Clin Cancer Res
|
2008
|
0.92
|
|
67
|
Colorectal cancer vaccines in clinical trials.
|
Expert Rev Vaccines
|
2011
|
0.92
|
|
68
|
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.
|
Cancer Immunol Immunother
|
2011
|
0.92
|
|
69
|
Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer.
|
Int J Cancer
|
2008
|
0.89
|
|
70
|
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.
|
Cancer Immunol Immunother
|
2013
|
0.89
|
|
71
|
2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.
|
Bioorg Med Chem Lett
|
2009
|
0.89
|
|
72
|
Characterization of antigen-specific immune responses induced by canarypox virus vaccines.
|
J Immunol
|
2007
|
0.88
|
|
73
|
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
|
Gastroenterology
|
2008
|
0.88
|
|
74
|
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.
|
Cancer Immunol Immunother
|
2012
|
0.88
|
|
75
|
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
|
Int J Cancer
|
2012
|
0.88
|
|
76
|
Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer.
|
Int J Cancer
|
2005
|
0.88
|
|
77
|
Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
|
J Immunother
|
2011
|
0.87
|
|
78
|
CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population.
|
J Immunol
|
2010
|
0.86
|
|
79
|
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.
|
Cancer Immunol Immunother
|
2012
|
0.86
|
|
80
|
Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.
|
J Immunol
|
2012
|
0.85
|
|
81
|
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia.
|
Int J Cancer
|
2008
|
0.85
|
|
82
|
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.
|
Cancer Immunol Immunother
|
2014
|
0.85
|
|
83
|
TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
|
J Clin Invest
|
2016
|
0.85
|
|
84
|
Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.
|
Cancer Gene Ther
|
2003
|
0.84
|
|
85
|
Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses.
|
J Infect Dis
|
2010
|
0.84
|
|
86
|
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells.
|
Mol Immunol
|
2008
|
0.83
|
|
87
|
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.
|
Cancer Immunol Immunother
|
2015
|
0.83
|
|
88
|
Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
|
Pigment Cell Melanoma Res
|
2015
|
0.83
|
|
89
|
Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires.
|
Eur J Immunol
|
2011
|
0.83
|
|
90
|
Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.
|
J Transl Med
|
2014
|
0.82
|
|
91
|
New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation.
|
J Immunol
|
2013
|
0.82
|
|
92
|
Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.
|
Cancer Immunol Immunother
|
2013
|
0.82
|
|
93
|
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.
|
Cytometry A
|
2014
|
0.81
|
|
94
|
Influenza matrix 1-specific human CD4+ FOXP3+ and FOXP3(-) regulatory T cells can be detected long after viral clearance.
|
Eur J Immunol
|
2010
|
0.81
|
|
95
|
Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival.
|
Int J Cancer
|
2014
|
0.81
|
|
96
|
Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
|
Int J Cancer
|
2011
|
0.81
|
|
97
|
Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity.
|
Adv Immunol
|
2012
|
0.81
|
|
98
|
The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
|
Anticancer Agents Med Chem
|
2014
|
0.81
|
|
99
|
Competition-based cellular peptide binding assay for HLA class I.
|
Curr Protoc Immunol
|
2004
|
0.80
|
|
100
|
Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia.
|
Int J Cancer
|
2014
|
0.80
|
|
101
|
Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.
|
Pigment Cell Melanoma Res
|
2014
|
0.79
|
|
102
|
T-regulatory cells in tumour-specific vaccination strategies.
|
Expert Opin Biol Ther
|
2008
|
0.79
|
|
103
|
Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines.
|
Bioorg Med Chem Lett
|
2006
|
0.79
|
|
104
|
Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.
|
J Transl Med
|
2011
|
0.79
|
|
105
|
Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
|
Int J Cancer
|
2007
|
0.77
|
|
106
|
Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy.
|
Expert Rev Vaccines
|
2012
|
0.77
|
|
107
|
Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma.
|
Cancer Immunol Immunother
|
2015
|
0.77
|
|
108
|
Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.
|
Expert Rev Vaccines
|
2013
|
0.77
|
|
109
|
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
|
Vaccine
|
2004
|
0.75
|
|
110
|
Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasia.
|
Int J Gynecol Cancer
|
2013
|
0.75
|
|
111
|
Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma.
|
JAMA Ophthalmol
|
2014
|
0.75
|
|
112
|
Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma.
|
Nat Med
|
2016
|
0.75
|